These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 11753908

  • 1. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
    Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, Howard R, Davis GL.
    Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
    [Abstract] [Full Text] [Related]

  • 2. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ.
    Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
    [Abstract] [Full Text] [Related]

  • 3. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
    Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, Maxwell P, Halff G.
    Transplantation; 2001 Nov 27; 72(10):1675-9. PubMed ID: 11726831
    [Abstract] [Full Text] [Related]

  • 4. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
    Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, Madariaga J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplant Proc; 2005 Mar 27; 37(2):1217-9. PubMed ID: 15848674
    [Abstract] [Full Text] [Related]

  • 5. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG.
    Liver Transpl; 2011 Dec 27; 17(12):1394-403. PubMed ID: 21850690
    [Abstract] [Full Text] [Related]

  • 6. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
    Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplantation; 2007 Oct 15; 84(7):829-35. PubMed ID: 17984834
    [Abstract] [Full Text] [Related]

  • 8. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA.
    Transplant Proc; 2005 Dec 15; 37(10):4373-9. PubMed ID: 16387124
    [Abstract] [Full Text] [Related]

  • 9. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
    Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC.
    Am J Transplant; 2002 Jul 15; 2(6):568-73. PubMed ID: 12118902
    [Abstract] [Full Text] [Related]

  • 10. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG.
    Transplantation; 2000 Jan 27; 69(2):307-11. PubMed ID: 10670644
    [Abstract] [Full Text] [Related]

  • 11. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
    Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C, Eckhoff DE, Netto GJ, Katz E.
    Liver Transpl; 2007 Nov 27; 13(11):1521-31. PubMed ID: 17969201
    [Abstract] [Full Text] [Related]

  • 12. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar 27; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 13. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun 15; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 15. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J, Arns W, Marti HP, Hauss J, Ketteler M, Beckurts T, Boesmueller C, Pohanka E, Martin PY, Gerhardt M, Farese S, Neumayer HH, Floege J, Gurr C, Budde K, DACH Study Group.
    Nephrol Dial Transplant; 2010 Jan 15; 25(1):283-92. PubMed ID: 19773417
    [Abstract] [Full Text] [Related]

  • 16. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 15; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
    Abramowicz D, Vanrenterghem Y, Squifflet JP, Kuypers D, Mourad M, Meurisse M, Wissing M.
    Clin Transplant; 2005 Aug 15; 19(4):475-82. PubMed ID: 16008591
    [Abstract] [Full Text] [Related]

  • 18. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
    Kornberg A, Küpper B, Tannapfel A, Hommann M, Scheele J.
    Int Immunopharmacol; 2005 Jan 15; 5(1):107-15. PubMed ID: 15589468
    [Abstract] [Full Text] [Related]

  • 19. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P.
    Am J Gastroenterol; 1997 Sep 15; 92(9):1453-7. PubMed ID: 9317061
    [Abstract] [Full Text] [Related]

  • 20. Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience.
    Post M, Raszeja-Wyszomirska J, Jarosz K, Lubikowski J, Wasilewicz M, Mydłowska M, Milkiewicz P, Wójcicki M.
    Transplant Proc; 2009 Oct 15; 41(8):3107-9. PubMed ID: 19857687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.